Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
AnaptysBio, Inc. is a clinical-stage biotechnology company specializing in innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead product, rosnilimab, targets PD-1+ T cells and is in Phase 2b trials for rheumatoid arthritis and ulcerative colitis. With a focus on underserved patient populations, AnaptysBio aims to leverage its antibody pipeline and collaborations, including with GlaxoSmithKline, to address significant market opportunities in immunology.
This description was generated via AI from an annual report. Updated about 1 year ago.